Accurate Mammogram Reading More Likely Following Mammotome Biopsy, Study Indicates

News
Article
OncologyONCOLOGY Vol 12 No 7
Volume 12
Issue 7

Mammotome biopsy causes significantly less internal breast scarring than open surgical biopsy and is less likely to interfere with a radiologist’s ability to read subsequent mammograms, according to a new study presented at the third annual

Mammotome biopsy causes significantly less internal breast scarring than open surgical biopsy and is less likely to interfere with a radiologist’s ability to read subsequent mammograms, according to a new study presented at the third annual Multidisciplinary Symposium on Breast Disease in Amelia Island, Florida, a medical conference of radiologists and surgeons specializing in breast disease.

The study indicates that, compared to Mammotome biopsy, internal scarring from open surgical breast biopsy is more than twice as likely to influence the radiologist’s ability to read a subsequent mammogram. Researchers also found that open surgical biopsy caused nearly twice as much internal scarring as did Mammotome biopsy.

Scarring and Mammography

The study suggests that women who have open surgical biopsy are more likely to develop changes on future mammograms than are women who have had a Mammotome biopsy, said lead author Catherine A. Kusnick, MD, assistant professor of radiology at the University of Iowa College of Medicine. These changes may require additional mammographic evaluation on future mammograms.

Scarring from open surgical biopsy influenced the confidence level in reading mammograms in more than 72% of cases studied. In contrast, Mammotome biopsy influenced the confidence level in only 29.5% of cases studied.

"This is a significant improvement. Post biopsy scarring can sometimes mimic or mask subtle breast cancers. The reduced rate of scarring from Mammotome biopsy compared to surgical biopsy may make it easier for radiologists to read future mammograms," said Dr. Kusnick.

Researchers identified scarring on one-half of mammograms following open surgical biopsy, as compared with only 27.3% of mammograms following Mammotome biopsy.

The study involved five radiologists specializing in mammography but with different experience levels, who were blinded to biopsy technique, breast lesion location, and identifying features. The radiologists examined two sets of mammograms, 14 surgical and 19 Mammotome cases. Even with the relatively small number of cases, the methodology and findings indicate significant statistical accuracy for the study, Dr. Kusnick said.

Minimally Invasive

Mammotome biopsy allows women to have a quick, minimally invasive breast biopsy. During the half-hour, outpatient procedure, the physician inserts a sampling probe through a small nick in the patient’s breast, which does not have to be repeatedly removed and inserted. Following the biopsy, the patient goes home with a small adhesive strip to cover the skin nick.

Open surgical biopsy, by comparison, is a more costly, time-consuming process that requires anesthesia, an operating room, and sutures.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Related Content